Press Releases

 
Press Releases
  Date Title View
Nov 7, 2016
LEXINGTON, MA -- (Marketwired) -- 11/07/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced an upcoming poster presentation at the 2016 American College of Allergy, Asthma and Immunology Annual Scientific Meeting to be h...
PDF
Sep 26, 2016
LEXINGTON, MA -- (Marketwired) -- 09/26/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) First-Ever Vehicle-Controlled Phase III Clinical Trial in Noninfectious Anterior Uveitis First-Ever Phase III Clinical Trial in Sjögren-Larsson Syndrome Allergic Conjunctivitis Phase IIb Clinical Trial Phase II...
PDF
Sep 14, 2016
LEXINGTON, MA -- (Marketwired) -- 09/14/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced the appointment of Richard H. Douglas, Ph.D. to the Board of Directors of the Company. "We are extremely pleased that...
PDF
Sep 9, 2016
LEXINGTON, MA -- (Marketwired) -- 09/09/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will host a Research and Development Day to discuss the company's late-stage clinical programs in ocular inflammation and...
PDF
Aug 10, 2016
LEXINGTON, MA -- (Marketwired) -- 08/10/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today reported second quarter financial results and provided a corporate update. "We are extremely pleased with our progress through ...
PDF
Aug 9, 2016
LEXINGTON, MA -- (Marketwired) -- 08/09/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today reported positive data from a randomized, parallel-group, double-blind, vehicle-controlled, multi-center clinical trial of topical dermatol...
PDF
Aug 8, 2016
LEXINGTON, MA -- (Marketwired) -- 08/08/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that, on Tuesday, August 9, 2016, prior to the market open, it will report the results of a randomized, parallel-group, double-b...
PDF
Aug 4, 2016
LEXINGTON, MA -- (Marketwired) -- 08/04/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the Canaccord Genuity Annual Growth Conference on...
PDF
Aug 3, 2016
LEXINGTON, MA -- (Marketwired) -- 08/03/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will issue its financial results for the second quarter ended June 30, 2016 on Wednesday, August 10, 2016, prior to the ...
PDF
Jun 7, 2016
LEXINGTON, MA -- (Marketwired) -- 06/07/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that the last patient has completed dosing in Aldeyra's randomized, parallel-group, double-masked, vehicle-controlled Phase II c...
PDF
Page: FirstPrevious
2
... NextLast